Collegium Pharmaceutical, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Collegium Pharmaceutical, Inc. announced a significant increase in net product revenues for 2025, primarily fueled by the full-year contribution of Jornay PM and strategic acquisitions.
NASDAQ
Collegium Pharmaceutical's 2024 results show revenue growth driven by the acquisition of Ironshore and increased sales of Belbuca and Xtampza ER, despite declines in Nucynta Products revenue.
NASDAQ
Collegium Pharmaceutical details its stock incentive plan and reports its 2023 annual financial results, highlighting revenue growth and strategic shifts.